XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancerSuppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsProfile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.Emerging therapies to prevent skeletal morbidity in men with prostate cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerXL184 (cabozantinib) for medullary thyroid carcinoma.Management of medullary thyroid cancer.Multikinase inhibitors: a new option for the treatment of thyroid cancer.Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).Cabozantinib for the treatment of advanced medullary thyroid cancer.From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.Angiogenesis and anti-angiogenic therapy in prostate cancer.Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.Expression and clinical relevance of MET and ALK in Ewing sarcomas.Cabozantinib as a novel therapy for renal cell carcinoma.Second-line treatment options in hepatocellular carcinomaReal-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumDifferential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplificationCabozantinib in prostate cancer: the beginning of a precision paradigm?Cabozantinib approved for advanced medullary thyroid cancerCabozantinib in Patients With Hepatocellular Carcinoma (ACTION)Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCabozantinib in the Elderly With Metastatic Renal Cell Carcinoma
P921
Q27919563-57CEF22F-046D-4043-9F94-7978E168528BQ28371428-748547BA-E5A9-41EE-B3EE-6104C1899074Q28371671-7B3E2E7E-89AF-4CBC-975E-05E33EA8D285Q28445019-ACEA1F67-AE03-498A-9862-D94DB4F6AB76Q28445133-74AE5793-B2E5-43E7-A73D-46A893FA51F3Q28445134-458AECF8-8F62-4CB3-B7E5-5931B7420A45Q32965629-22CDAD35-C245-4F49-9EC3-0CDA73BC7664
P3354
description
Cabozantinib
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Cabozantinib
@nl
Kabozantinib
@sh
Kabozantinib
@sr
Kabozantynib
@pl
Tyrosin Kinase Inhibitor
@de
cabozantinib
@en
cabozantinib
@fr
cabozantinib
@pt
kabozantinib
@nn
קבוזנטיניב
@he
type
label
Cabozantinib
@nl
Kabozantinib
@sh
Kabozantinib
@sr
Kabozantynib
@pl
Tyrosin Kinase Inhibitor
@de
cabozantinib
@en
cabozantinib
@fr
cabozantinib
@pt
kabozantinib
@nn
קבוזנטיניב
@he
altLabel
BMS 907351
@en
BMS-907351
@en
BMS907351
@en
Cabometyx®
@en
Cabozantinib
@en
Cometriq
@de
Cometriq
@pt
Cometriq®
@en
XL 184
@en
XL-184
@en
prefLabel
Cabozantinib
@nl
Kabozantinib
@sh
Kabozantinib
@sr
Kabozantynib
@pl
Tyrosin Kinase Inhibitor
@de
cabozantinib
@en
cabozantinib
@fr
cabozantinib
@pt
kabozantinib
@nn
קבוזנטיניב
@he
P2175
P592
P6366
P661
P662
P665
P683
P117
P1579
P2067
501.169999
P2115
N0000186139